newsfilter
← Latest News
GlobeNewswire·

Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline assets SB019, for the treatment of SARS-CoV-2,